Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
CJC-1295 and Ipamorelin are investigational peptides studied for their effects on growth hormone (GH) signaling. CJC-1295 is a long-acting analog of growth hormone–releasing hormone (GHRH); human studies have shown that it can increase circulating GH and IGF-1 concentrations while preserving pulsatile GH secretion.
Ipamorelin is a synthetic growth-hormone secretagogue that acts through the ghrelin/GH-secretagogue receptor. Experimental research has demonstrated its ability to stimulate GH release, although available human clinical evidence remains limited.
Research involving these peptides has focused on growth-hormone physiology, endocrine signaling, metabolism, and related biological pathways. However, the CJC-1295 + Ipamorelin combination has not been established as safe or effective for therapeutic use, and FDA has identified safety concerns and limited clinical data for both substances.
For laboratory research use only. Not for human consumption.
CJC-1295 and Ipamorelin are investigational peptides studied for their effects on growth hormone (GH) signaling. CJC-1295 is a long-acting analog of growth hormone–releasing hormone (GHRH); human studies have shown that it can increase circulating GH and IGF-1 concentrations while preserving pulsatile GH secretion.
Ipamorelin is a synthetic growth-hormone secretagogue that acts through the ghrelin/GH-secretagogue receptor. Experimental research has demonstrated its ability to stimulate GH release, although available human clinical evidence remains limited.
Research involving these peptides has focused on growth-hormone physiology, endocrine signaling, metabolism, and related biological pathways. However, the CJC-1295 + Ipamorelin combination has not been established as safe or effective for therapeutic use, and FDA has identified safety concerns and limited clinical data for both substances.
For laboratory research use only. Not for human consumption.